CureVac NV
NASDAQ:CVAC

Watchlist Manager
CureVac NV Logo
CureVac NV
NASDAQ:CVAC
Watchlist
Price: 2.99 USD 1.01% Market Closed
Market Cap: 670.7m USD
Have any thoughts about
CureVac NV?
Write Note

CureVac NV
Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

CureVac NV
Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
CureVac NV
NASDAQ:CVAC
Operating Expenses
-€207.2m
CAGR 3-Years
-13%
CAGR 5-Years
-25%
CAGR 10-Years
N/A
BioNTech SE
NASDAQ:BNTX
Operating Expenses
-€2.3B
CAGR 3-Years
-66%
CAGR 5-Years
-69%
CAGR 10-Years
N/A
MorphoSys AG
XETRA:MOR
Operating Expenses
-€611.1m
CAGR 3-Years
-25%
CAGR 5-Years
-37%
CAGR 10-Years
-25%
Immatics NV
NASDAQ:IMTX
Operating Expenses
-€155.7m
CAGR 3-Years
-16%
CAGR 5-Years
-32%
CAGR 10-Years
N/A
Biotest AG
XETRA:BIO
Operating Expenses
-€150.8m
CAGR 3-Years
-7%
CAGR 5-Years
-5%
CAGR 10-Years
1%
Formycon AG
XETRA:FYB
Operating Expenses
-€23.3m
CAGR 3-Years
-18%
CAGR 5-Years
-15%
CAGR 10-Years
N/A
No Stocks Found

CureVac NV
Glance View

Market Cap
670.8m USD
Industry
Biotechnology

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 500 full-time employees. The company went IPO on 2020-08-14. The firm is engaged in the therapeutic development of messenger Ribonucleic Acid (mRNA) and RNA-based vaccines. CureVac AG focuses on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. The firm's pipeline focuses on three areas: cancer immunotherapy, prophylactic vaccines, and protein-based therapies.

CVAC Intrinsic Value
4.32 USD
Undervaluation 31%
Intrinsic Value
Price

See Also

What is CureVac NV's Operating Expenses?
Operating Expenses
-207.2m EUR

Based on the financial report for Dec 31, 2023, CureVac NV's Operating Expenses amounts to -207.2m EUR.

What is CureVac NV's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-25%

Over the last year, the Operating Expenses growth was -55%. The average annual Operating Expenses growth rates for CureVac NV have been -13% over the past three years , -25% over the past five years .

Back to Top